NAVB News and Press, Navidea Biopharmaceuticals Inc. From 04/18/22

Navidea Biopharma (NYSE:NAVB) stock rose +16.3% post market after it said India approved its Lymphoaim imaging (Tc99m tilmanocept) in patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity. Tc99m tilmanocept is designed to ...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the regulatory approval of Lymphoaim (“Lymphoseek...

Navidea Biopharmaceuticals (NYSE:NAVB) shares surged 12% during Tuesday extended trading on receipt of an acceptance letter from the NYSE American. The biopharmaceutical company company received a notification from the NYSE American back in Jan stating that it was not in compliance ...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has adopted a Section 382 Rights...

As previously disclosed, on January 28, 2022, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a notification from t...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today welcomed Kenneth Berger, Ph.D., as Senior Regulatory Consultant, and t...

Navidea (NAVB -13.0%) stock declined after Q4 revenue declined -77.04% Y/Y to ~$50K. FY21 revenue decreased -41.91% Y/Y to $0.53M. The company said the decline was mainly due to decreased grant revenue from the National Institutes of Health supporting Manocept development and fall in royalty ...

Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Earnings Conference Call March 23, 2022 17:00 ET Company Participants Michael Rosol - Chief Medical Officer Erika Eves - Vice President, Finance and Administration Conference Call Participants Edward English - Private Investor Presentation Opera...

Conference Call to be held Wednesday, March 23, 2022 at 5:00 pm (EST) This press release is being re-issued to revise the language in the Selling, General and Administrative bullet under Financial Results. That third bullet, third sentence should read: The net increase durin...

Navidea Biopharm press release (NYSE:NAVB): Q4 GAAP EPS of -$0.12. Revenue of $0.05M (-77.3% Y/Y). cash and cash equivalents of $4.2M For further details see: Navidea Biopharm GAAP EPS of -$0.12, revenue of $0.05M